{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:35:57Z","timestamp":1768408557567,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Patients with cancer often experience nausea and vomiting (N\/V), but may have difficulty using olanzapine (OLZ), a common antiemetic. Asenapine (ASE) is a multi\u2010acting receptor\u2010targeted antipsychotic like OLZ, although there is little evidence that ASE serves as an antiemetic. The aim of this study was to evaluate the efficacy and tolerability of ASE compared to those of OLZ for the treatment of N\/V in patients with cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study involved patients who received 5\u2009mg ASE, 5\u2009mg OLZ, or 2.5\u2009mg OLZ for 2\u2009days. Daily worst N\/V was rated on a scale of 0 (none) to 3 (very much). The primary endpoint was the proportion of patients who had a response, defined as any reduction in N\/V score. A complete response (CR) was defined as a score reduction to 0. Secondary endpoints included the proportion of patients with CR and adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between April 2017 and March 2023, 212 patients were enrolled to receive treatment: 5\u2009mg ASE (<jats:italic>n<\/jats:italic>\u2009=\u200934), 5\u2009mg OLZ (<jats:italic>n<\/jats:italic>\u2009=\u2009102), or 2.5\u2009mg OLZ (<jats:italic>n<\/jats:italic>\u2009=\u200976). No significant differences in response rates (52.9% vs. 58.8% vs. 52.6%, <jats:italic>p<\/jats:italic>\u2009=\u20090.671) or secondary endpoints were observed between the groups. Patients receiving ASE were more likely to experience oral hypoesthesia (<jats:italic>p<\/jats:italic>\u2009=\u20090.004).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This preliminary study suggests that ASE may be effective for N\/V. Further studies are required to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.1002\/npr2.12412","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T08:00:48Z","timestamp":1705651248000},"page":"158-164","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study"],"prefix":"10.1002","volume":"44","author":[{"given":"Tomohiko","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Psychiatry Kitasato University School of Medicine  Sagamihara\u2010shi Japan"},{"name":"Department of Psychiatry Kitasato University Graduate School of Medical Sciences  Sagamihara\u2010shi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Kanai","sequence":"additional","affiliation":[{"name":"Department of Research and Development Center for New Medical Frontiers Kitasato University School of Medicine  Sagamihara\u2010shi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Muraoka","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Kitasato University School of Medicine  Sagamihara\u2010shi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Kitasato University School of Medicine  Sagamihara\u2010shi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Ara","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Kitasato University School of Medicine  Sagamihara\u2010shi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-4588","authenticated-orcid":false,"given":"Ken","family":"Inada","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Kitasato University School of Medicine  Sagamihara\u2010shi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00470"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldq031"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1574-9"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-005-0897-1"},{"issue":"5","key":"e_1_2_11_6_1","first-page":"476","article-title":"Nausea and vomiting not related to cancer therapy: intractable problem or clinical challenge?","volume":"11","author":"Wickham RJ","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00391-3"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1052"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30678-3"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2017.09.027"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1220-8"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115797"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.2313"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7386.433"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2012-1052"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0115-5"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082944"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.06.030"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.11.321"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029942"},{"key":"e_1_2_11_22_1","first-page":"855","article-title":"Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV study Group of Japan","volume":"20","author":"Tamura K","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.8375"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20567"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211035269"},{"issue":"6","key":"e_1_2_11_26_1","first-page":"803","article-title":"Asenapine review, part II: clinical efficacy, safety and tolerability","volume":"13","author":"Citrome L","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"e_1_2_11_27_1","article-title":"Efficacy and safety of HP\u20103070, an asenapine transdermal system, in patients with schizophrenia: a phase 3, randomized, placebo\u2010controlled study","volume":"82","author":"Citrome L","year":"2021","journal-title":"J Clin Psychiatry"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T05:54:31Z","timestamp":1732773271000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/npr2.12412"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12412","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"2023-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}